生命科学资讯

Roche's return to RNA continues with $1.7B deal for Sanegene program

Roche continues RNA return with $1.7B deal for Sanegene drug - Fierce Biotech

Roche Expands Clinical Research in Mexico, Invests MX$1.2 Billion - Mexico Business News

Roche’s 2025 profit blunted by weakened US dollar - Medical Device Network

Roche’s 2025 profit blunted by weakened US dollar - Pharmaceutical Technology

Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales

Roche GLP-1 produces “robust” weight loss in late-stage obesity trial - European Pharmaceutical Review

Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout - Fierce Biotech

Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist | PharmExec - Pharmaceutical Executive

Roche, trailing in obesity, showcases new data for GLP-1 shot

How Roche is Scaling Production After Obesity Breakthrough - Manufacturing Digital Magazine

Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial - Fierce Biotech

Roche announces positive phase II results for experimental obesity drug - wkzo.com

Roche's Gazyva gets Health Canada approval for lupus nephritis - marketscreener.com

Roche boosts NC factory investment to $2B; Rentschler CEO steps down

Anthropic, Roche & NVIDIA: This Week's Top Stories - Healthcare Digital

Roche: Making Preventative Healthcare Accessible to All - Healthcare Digital

Chutes & Ladders—Former Roche oncology head turns to Tubulis

Former Roche oncology head turns to Tubulis—Chutes & Ladders - fiercebiotech.com

Roche returns to Chinese biotech MediLink for another ADC pact